Tarceva

Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer

OSI-774 (Erlotinib, Tarceva) in Elderly Patients

A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma

Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer

Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)

Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC

A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors